The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Deutsche Bank analyst James Shin maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of ...

Eli Lilly ($LLY) is considering testing its blockbuster weight-loss drugs in individuals who are not yet overweight but are ...

The longshoreman’s strike shutting down ports along the East and Gulf Coasts may cause a significant shortage of widely used ...

Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...

The effectiveness can vary based on the individual response and adherence to treatment. Research indicates that GLP-1 ...

A study from tirzepatide's manufacturer found that the GLP-1 drug could significantly improve heart failure symptoms.